Card Fail News Today

AB-1002 is being studied for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms

AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms1GenePHIT is a clinical trial to evaluate the safety and efficacy of the one-time administration of AB-1002 and will include the largest number...

GenePHIT, which is now enrolling, will study AB-1002 in adults with NYHA Class III Heart Failure and non-ischemic cardiomyopathy 

/PRNewswire/ -- Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today...

Injectafer is an intravenous (IV) iron replacement therapy indicated for adult patients with heart failure who have iron deficiency 

Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, have announced that the U.S. Food and Drug Administration (FDA) approved INJECTAFER (ferric carboxymaltose injection) for the treatment of iron deficiency in adult patients with heart failure categorized as New York Heart Association class II/III to improve exercise capacity. The company reported that with this approval, INJECTAFER is now the first and only intravenous (IV) iron replacement therapy indicated for ad...

INJECTAFER is now the first and only intravenous iron replacement therapy indicated for adult patients with heart failure who have iron deficiency ... | June 5, 2023

Corvia Atrial Shunt has the potential to change the way heart failure is treated TEWKSBURY, Mass., Dec. 6, 2022 /PRNewswire/ -- Corvia Medical, Inc., a company dedicated to transforming

An intensive treatment strategy of rapid up-titration of guideline-directed medication and close follow-up after an acute heart failure admission was readily accepted by patients because it reduced symptoms, improved quality of life, and reduced the risk of 180-day all-cause death or heart failure readmission compared with usual care.

Ancel Keys’ religious certainty made him the disciple for the promotion of what would become a politically and commercially-driven agenda.